Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Short Interest Up 30.6% in March

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 6,400 shares, an increase of 30.6% from the February 28th total of 4,900 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 43,900 shares, the short-interest ratio is currently 0.1 days.

Emmaus Life Sciences Stock Performance

Shares of OTCMKTS EMMA traded down $0.00 during trading hours on Monday, hitting $0.02. The company’s stock had a trading volume of 11,093 shares, compared to its average volume of 46,039. Emmaus Life Sciences has a 12 month low of $0.00 and a 12 month high of $0.12. The stock has a market cap of $1.09 million, a price-to-earnings ratio of -0.19 and a beta of 6.47. The business has a 50-day simple moving average of $0.02 and a 200-day simple moving average of $0.02.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.